India’s anti-obesity drug market has seen tremendous growth over the past five years, with market researcher PharmaTrac reporting a more than fourfold increase to Rs 576 crore as of March 2025. This growth can be attributed to the rise in lifestyle diseases, increased affordability, and a willingness among the population to pay for weight-loss treatments.
The key driver of this market has been the semaglutide pill Rybelsus from Novo Nordisk, which now commands 69% of the market at Rs 397 crore. The recent launch of Eli Lilly’s Mounjaro, a once-weekly injectable drug for weight management and type 2 diabetes, has further bolstered the acceptance of weight loss products in India.
Other popular anti-obesity drugs in the market include orlistat, dulaglutide, and liraglutide. The rise in lifestyle diseases and the willingness to pay for treatment has made the anti-obesity segment a fast-growing market.
Adult obesity affects nearly 100 million people in India, and is increasingly linked to conditions like type 2 diabetes, hypertension, and cardiovascular ailments. The introduction of new-generation therapies like semaglutide and Mounjaro have changed the treatment landscape by offering benefits beyond weight loss, such as improved blood sugar control.
Experts believe that the obesity drug market in India is poised for accelerated growth, driven by increased disease awareness, evolving treatment protocols, and the introduction of new weight-loss drugs. The arrival of innovative therapies signals a new phase in how obesity is managed clinically.
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
